Eli Lilly and Company (NEO:ZLLY)
Canada · Delayed Price · Currency is CAD | Market Cap | 1.50T +65.0% |
| Revenue (ttm) | 113.13B +49.6% |
| Net Income | 37.93B +93.6% |
| EPS | 42.30 +94.8% |
| Shares Out | n/a |
| PE Ratio | 39.44 |
| Forward PE | 28.87 |
| Dividend | 0.05 (0.41%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 182 |
| Open | 12.59 |
| Previous Close | 12.21 |
| Day's Range | 12.57 - 12.60 |
| 52-Week Range | 9.09 - 13.31 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Novo vs. Eli Lilly: Study Shows Ozempic Advantage over Mounjaro — Why This Matters for NVO Investors
Danish drug giant Novo ($NVO), in a Tuesday press statement, announced key findings from a real-world study that pitched its diabetes drug against Eli Lilly’s ($LLY) medication. The study is…
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro
Novo Nordisk said on Tuesday a real-world study found that adults with type 2 diabetes who took an escalated dose of its diabetes drug, Ozempic, had a lower risk of major cardiovascular events compa...
Eli Lilly’s Zepbound shows improved weight loss vs. Wegovy in new analysis
Eli Lilly (LLY) announced results from a new analysis showing that Zepbound – tirzepatide – 10 mg and 15 mg, a dual GIP and GLP-1 receptor agonist, delivered greater weight…
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
In this new analysis, Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesity Participants receiving Zepbound 15 mg had more than three times the odds of achieving at leas...
Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis
Eli Lilly said its oral obesity drug, Foundayo, offers greater weight loss and better blood sugar control than a higher dose of Novo Nordisk's Ozempic pill in adults with type 2 diabetes, citing dat...
Eli Lilly announces positive results from study of Foundayo 17.2 mg
Eli Lilly (LLY) and Company announced results from a new analysis showing that Foundayo 17.2 mg was associated with significantly greater weight loss and better blood sugar control than oral…
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks These additional analyses build on findings of the ACHIEVE-3 head-t...
Eli Lilly CEO tells Bloomberg sees more deals in untapped areas
Eli Lilly (LLY) CEO Dave Ricks said in an interview with Bloomberg that he sees the company doing more deals in untapped areas and sees deals that are “a little…
Eli Lilly price target raised to $1,500 from $1,400 at JPMorgan
JPMorgan raised the firm’s price target on Eli Lilly (LLY) to $1,500 from $1,400 and keeps an Overweight rating on the shares ahead of the Q3 report on October 29.
Eli Lilly launches ‘Lilly Change the Course Commitment’
Eli Lilly (LLY) and Company is launching the Lilly Change the Course Commitment, a new global health initiative that aims to achieve parity in patients treated with Lilly’s innovative diabetes…
Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs
Through this commitment, Lilly aims to expand access to its innovative diabetes and obesity medicines to as many people in resource-limited settings, including low- and middle-income countries (LMICs)...
Nektar awarded $90M in Eli Lilly breach of contract case
Nektar (NKTR) in 2023 filed a complaint in the U.S. District Court for the Northern District of California against Eli Lilly (LLY) alleging, among other claims, breach of contract and…
Nektar selloff on trial brings ‘strong entry point,’ says BTIG
BTIG says that while the $90M jury award is below the $1B initial amount Nektar (NKTR) appeared to expect in the Eli Lilly (LLY) case, completion of the litigation should…
Eli Lilly announces FDA approval of Olumiant
Eli Lilly (LLY) and Company announced that the U.S. FDA approved Olumiant, a once-daily pill, for the treatment of pediatric patients 12 years of age and older with severe alopecia…
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
FDA approval supported by data from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe alopecia areata (AA) Treatment with Olumiant res...
NTHM's Index Rebalance Puts Thematic Rotation to Work
The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP...
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, but faces an uphill battle to win back investors and obesity market share. Meanwh...
FDA approves Eli Lilly's once-weekly insulin injection for type 2 diabetes
The once-weekly treatment could reduce the number of injections by more than 300 per year compared with once-daily basal insulin, Eli Lilly said.
Eli Lilly Stock (LLY) Jumps 4% After FDA Approves Insulin for Type 2 Diabetes
The company is a leader in Diabetes treatments.
US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes
The US Food and Drug Administration has approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes, the drugmaker said on Thursday, offering patients an alternative to d...
Eli Lilly announces FDA approval of Onswik for type 2 diabetes
Eli Lilly (LLY) and Company announced the U.S. Food and Drug Administration approval of Onswik, a once-weekly basal insulin, indicated along with diet and exercise to control high blood sugar…
China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion
Chinese drugmaker InnoCare Pharma said on Thursday it entered into a research collaboration and license agreement with Eli Lilly that could be worth up to about $3.35 billion.
Nektar shares pressured by jury notes in Lilly case, says B. Riley
B. Riley analyst Mayank Mamtani says jury deliberations are headed to the fourth day today in Nektar’s (NKTR) breach of contract trial against Eli Lilly (LLY). The jury’s notes review…
Nektar price target lowered to $50 from $80 at Wedbush
Wedbush lowered the firm’s price target on Nektar (NKTR) to $50 from $80 and keeps a Neutral rating on the shares. Following “speculation on failed litigation” against Eli Lilly (LLY),…
Nektar dropped as jury deliberates suit against Eli Lilly
Nektar (NKTR) shares dropped yesterday as a federal jury in San Francisco continued to deliberate the company’s breach of contract lawsuit against Eli Lilly (LLY) regarding Rezpeg. Nektar claims Lilly...